Champions Oncology (CSBR) Asset Writedowns and Impairment (2015 - 2026)
Champions Oncology (CSBR) recorded quarterly Asset Writedowns and Impairment of -$30000.0 in Q1 2026, down 330.77% quarter-over-quarter from $13000.0 in Q4 2025, and up 25.0% on a YoY basis from -$24000.0 in Q1 2025.
Champions Oncology (CSBR) Asset Writedowns and Impairment (2015 - 2026) Analysis & Trends
Champions Oncology's Asset Writedowns and Impairment history runs 8 years deep, the most recent figure standing at -$30000.0 for Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment rose 25.0% year-over-year to -$30000.0; the TTM figure through Jan 2026 stood at $2000.0 (up 101.27% YoY), while the FY2025 annual figure was -$272000.0, down 157.14% from the prior year.
- Asset Writedowns and Impairment was -$30000.0 for Q1 2026 at Champions Oncology, down from $13000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $724000.0 in Q2 2023 to a low of -$209000.0 in Q4 2024.
- Historically, Asset Writedowns and Impairment has averaged $68928.6 across 5 years, with a median of $30500.0 in 2025.
- Biggest YoY gain for Asset Writedowns and Impairment was 270.21% in 2024; the steepest drop was 390.28% in 2024.
- A 5-year view of Asset Writedowns and Impairment shows it stood at $130000.0 in 2022, then plunged by 44.62% to $72000.0 in 2023, then slumped by 390.28% to -$209000.0 in 2024, then surged by 106.22% to $13000.0 in 2025, then plunged by 330.77% to -$30000.0 in 2026.
- The last three Asset Writedowns and Impairment figures came in at -$30000.0 (Q1 2026), $13000.0 (Q4 2025), and -$29000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -30,000.00 |
| Jan 31, 2026 | -30,000.00 |
| Oct 31, 2025 | 13,000.00 |
| Oct 31, 2025 | 13,000.00 |
| Jul 31, 2025 | -29,000.00 |
| Jul 31, 2025 | -29,000.00 |
| Apr 30, 2025 | 48,000.00 |
| Apr 30, 2025 | 48,000.00 |
| Jan 31, 2025 | -40,000.00 |
| Jan 31, 2025 | -40,000.00 |
| Oct 31, 2024 | -209,000.00 |
| Oct 31, 2024 | -209,000.00 |
| Jul 31, 2024 | -71,000.00 |
| Jul 31, 2024 | -71,000.00 |
| Apr 30, 2024 | 162,000.00 |
| Apr 30, 2024 | 162,000.00 |
| Jan 31, 2024 | 80,000.00 |
| Jan 31, 2024 | 80,000.00 |
| Oct 31, 2023 | 72,000.00 |
| Oct 31, 2023 | 72,000.00 |